Patents by Inventor Mark Andrake

Mark Andrake has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Human chorionic gonadotropin variant peptides and treatment of breast cancer
    Patent number: 11697674
    Abstract: The present disclosure provides hCG variant proteins, nucleic acid molecules encoding the same, vectors comprising nucleic acid molecules, compositions comprising the same, and methods of treating cancer.
    Type: Grant
    Filed: October 15, 2018
    Date of Patent: July 11, 2023
    Assignee: Institute For Cancer Research
    Inventors: Jose Russo, Yanrong Su, Julia Santucci Pereira Del Buono, Mark Andrake
  • HUMAN CHORIONIC GONADOTROPIN VARIANT PEPTIDES AND TREATMENT OF BREAST CANCER
    Publication number: 20220041679
    Abstract: The present disclosure provides hCG variant proteins, nucleic acid molecules encoding the same, vectors comprising nucleic acid molecules, compositions comprising the same, and methods of treating cancer.
    Type: Application
    Filed: October 15, 2018
    Publication date: February 10, 2022
    Applicant: Institute for Cancer Research d/b/a The Research Institute of Fox Chase Cancer Center
    Inventors: Jose Russo, Yanrong Su, Julia Santucci Pereira Del Buono, Mark Andrake
  • HUMAN CHORIONIC GONADOTROPIN VARIANT PEPTIDES AND TREATMENT OF BREAST CANCER
    Publication number: 20210188935
    Abstract: The present disclosure provides hCG variant proteins, nucleic acid molecules encoding the same, vectors comprising nucleic acid molecules, compositions comprising the same, and methods of treating cancer.
    Type: Application
    Filed: October 15, 2018
    Publication date: June 24, 2021
    Applicant: Institute for Cancer Research d/b/a The Research Institute of Fox Chase Cancer Center
    Inventors: Jose Russo, Yanrong Su, Julia Santucci Pereira Del Buono, Mark Andrake
  • Inhibition of human immunodeficiency virus integrase reaching dimer formation utilizing single-chain variable antibodies
    Patent number: 9533040
    Abstract: Methods to inhibit the formation of retrovirus integrase reaching dimers, to dissociate retrovirus integrase reaching dimers, and to stabilize retrovirus integrase reaching dimers in a conformation in which retrovirus DNA-to host cell DNA integration activity of the integrase is inhibited are provided. Methods for treating a retrovirus infection, which target retrovirus integrase reaching dimer formation and/or stability are also provided.
    Type: Grant
    Filed: June 21, 2013
    Date of Patent: January 3, 2017
    Assignee: Institute for Cancer Research
    Inventors: Anna Marie Skalka, Mark Andrake, Ravi Shankar Bojja
  • Systems and methods for diagnosing a predisposition to develop colon cancer
    Patent number: 9157124
    Abstract: Systems and methods for diagnosing or characterizing a predisposition to colon cancer are provided. Cell nuclei may be evaluated for the presence or quantity of gamma-H2AX foci. Nucleic acids may be evaluated for the presence, type, or quantity of genomic instability or surrogates of dsDNA breaks such as ataxia telangiectasia mutated (ATM), Rad3-related protein (ATR), and Tumor suppressor p53-binding protein 1 (53BP1) in gamma-H2AX foci. Nucleic acids comprising a germline nucleic acid sequence of the ERCC6, WRN, TERT, and FAAP100 genes may be sequenced or probed to determine if the nucleic acid sequence includes one or more alterations that cause genomic instability, dsDNA breaks, or gamma-H2AX foci or otherwise predispose a subject to develop colon cancer.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: October 13, 2015
    Assignee: Institute for Cancer Research
    Inventors: Greg H. Enders, Mark Andrake, Michael J. Hall, Biao Luo, Timothy J. Yen
  • SYSTEMS AND METHODS FOR DIAGNOSING A PREDISPOSITION TO COLON CANCER
    Publication number: 20150191797
    Abstract: Systems and methods for diagnosing or characterizing a predisposition to colon cancer are provided. Cell nuclei may be evaluated for the presence or quantity of gamma-H2AX foci or their total gamma-H2AX levels. Nucleic acids may be evaluated for the presence, type, or quantity of genomic instability or surrogates of dsDNA breaks such as ataxia telangiectasia mutated (ATM), Rad3-related protein (ATR), and Tumor suppressor p53-binding protein 1 (53BP1) in gamma-H2AX foci. Nucleic acids comprising a germline nucleic acid sequence of the ERCC6, WRN, TERT, SHPRH, and FAAP100 genes may be sequenced or probed to determine if the nucleic acid sequence includes one or more alterations that cause genomic instability, dsDNA breaks, or gamma-H2AX foci or otherwise predispose a subject to develop colon cancer.
    Type: Application
    Filed: March 18, 2015
    Publication date: July 9, 2015
    Inventors: GREG H. ENDERS, MARK ANDRAKE, MICHAEL J. HALL, BIAO LUO, TIMOTHY J. YEN
  • INHIBITING THE INTEGRATION OF RETROVIRUS DNA INTO HOST CELL DNA BY INHIBITING INTEGRASE REACHING DIMER FORMATION
    Publication number: 20130280271
    Abstract: Methods to inhibit the formation of retrovirus integrase reaching dimers, to dissociate retrovirus integrase reaching dimers, and to stabilize retrovirus integrase reaching dimers in a conformation in which retrovirus DNA-to host cell DNA integration activity of the integrase is inhibited are provided. Methods for treating a retrovirus infection, which target retrovirus integrase reaching dimer formation and/or stability are also provided.
    Type: Application
    Filed: June 21, 2013
    Publication date: October 24, 2013
    Inventors: Anna Marie Skalka, Mark Andrake, Ravi Shankar Bojja